Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (13264)	9/30/2004 6:19:25 PM
From: russet	Respond to of 52153

There are safety concerns I've heard with DMSO and cataracts. It certainly induces cataracts in some animal models. (There are some people though who think DMSO is the cure for everything.) This research is from the 1960's when pharmagrade DMSO was not available,...but it is clear this safety concern dogma lives on. No such side effect has been shown to occur with present day pharmagrade DMSO, and no such side effect occurred in humans, today or in the sixties when the biggies were testing it (J&J etc). Without the DMSO you cannot stop entry of the NSAID into systemic circulation, and you also cannot get the kind of efficacy the current studies with Pennsaid are getting (pain relief, improvement in mobility, cessation of swelling),...there is a 50% placebo effect with topicals of this nature, but the Pennsaid controls have shown the drug is far more effective than a placebo (in fact just as effective as an NSAID pill). Long term phase 4 studies are ongoing in the U.S. and Canada and this could be the information FDA wants for approval.